Detailed view for LmjF.22.0530

Basic information

TDR Targets ID: 24937
Leishmania major, peptidyl-prolyl cis-trans isomerase, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 6.8884 | Length (AA): 440 | MW (Da): 46523 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00498   FHA domain
PF00639   PPIC-type PPIASE domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0016853   isomerase activity  
GO:0005515   protein binding  
GO:0003755   peptidyl-prolyl cis-trans isomerase activity  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 7 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
66 177 1uht (A) 6 116 22.00 0.00000000011 0.99 0.64 -0.98
74 170 1gxc (A) 95 199 20.00 0 0.53 0.32 -1.08
273 440 1pin (A) 10 163 24.00 0 1 0.49 0.09
352 440 1zk6 (A) 119 205 36.00 0 0.98 0.6 -0.71
2 178 2n84 (A) 5 176 56.00 0 1 0.940473 0.57
56 172 4h87 (A) 150 275 38.00 0.000000000006 1 0.815309 -1.07
90 170 1r21 (A) 18 98 25.00 0 0.84 0.475291 -0.93

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile amastigotes, metacyclic. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_143132)

Species Accession Gene Product
Leishmania braziliensis LbrM.22.0480   peptidyl-prolyl cis-trans isomerase, putative
Leishmania donovani LdBPK_220410.1   peptidyl-prolyl cis-trans isomerase, putative
Leishmania infantum LinJ.22.0410   peptidyl-prolyl cis-trans isomerase, putative
Leishmania major LmjF.22.0530   peptidyl-prolyl cis-trans isomerase, putative
Leishmania mexicana LmxM.22.0530   hypothetical protein, conserved
Trypanosoma brucei gambiense Tbg972.7.2770   peptidyl-prolyl cis-trans isomerase, putative
Trypanosoma brucei Tb927.7.2480   peptidyl-prolyl cis-trans isomerase, putative
Trypanosoma congolense TcIL3000_7_1800   peptidyl-prolyl cis-trans isomerase, putative
Trypanosoma cruzi TcCLB.509207.130   peptidyl-prolyl cis-trans isomerase
Trypanosoma cruzi TcCLB.506857.60   peptidyl-prolyl cis-trans isomerase, putative

Essentiality

LmjF.22.0530 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb927.7.2480 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb927.7.2480 Trypanosoma brucei significant loss of fitness in bloodstream forms (6 days) alsford
Tb927.7.2480 Trypanosoma brucei no significant loss or gain of fitness in procyclic forms alsford
Tb927.7.2480 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0158 0.2606 0.2381
0.0142 0.2527 0
0.0047 0.2856 0.2926
0.0154 0.2818 0
0.0139 0.2817 0.2772
0.0158 0.2606 0.2381
0.0045 0.2718 0
0.0169 0.2736 0.2428
0.0012 0.2845 0.0931
0.0145 0.2815 0.2866
0.0065 0.2621 0.2431
0.0158 0.2838 0.2877
0.0145 0.2695 0.2763

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.22.0530 (Leishmania major), peptidyl-prolyl cis-trans isomerase, putative
Title for this comment
Comment